LLY 8-K Current Reports
ELI LILLY & Co - 241 current reports
ELI LILLY & Co 8-K Report, Corporate Update (May 20, 2026)
Eli Lilly and Company (LLY) has announced the successful completion of a significant debt offering, raising approximately $8.94 billion in net proceeds. This offering comprised multiple tranches of both floating rate and fixed rate notes with varying maturity dates and interest rates, ranging from 2028 to 2066. The issuance of these notes was registered under a Form S-3 shelf registration statement, indicating Lilly's proactive capital management strategy. The substantial capital infusion is poised to support the company's ongoing operations, strategic initiatives, and potential future investments. A notable aspect of this offering is the conditional mandatory redemption for certain series of notes tied to the consummation of the 'Centessa Acquisition'. Should this acquisition not proceed under specified conditions, specific series of notes will be subject to redemption at 101% of their principal amount, plus accrued interest, highlighting a potential contingent liability for the company dependent on M&A outcomes.
ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 7, 2026)
Eli Lilly and Company (LLY) held its 2026 Annual Meeting of Shareholders on May 4, 2026, with a strong turnout of approximately 90% of outstanding shares participating in the vote. Key outcomes include the re-election of four directors, Carolyn Bertozzi, William Kaelin, Jr., Jon Moeller, and David Ricks, to three-year terms. Additionally, shareholders provided advisory approval for the compensation of named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026, both with significant support. However, two significant proposals to amend the Company's Articles of Incorporation, one to eliminate the classified board structure and another to remove supermajority voting provisions, failed to gain the required 80% approval from outstanding shares. Furthermore, shareholder proposals requesting an independent board chair and an annual lobbying report were also not approved. These voting results indicate continued shareholder confidence in the current board and executive compensation practices, while also highlighting resistance to certain governance structure changes at this time.
ELI LILLY & Co 8-K Report, Financial Results (Apr 30, 2026)
Eli Lilly and Company (LLY) has filed a Current Report on Form 8-K dated April 30, 2026, to announce its financial results for the quarter ended March 31, 2026. The report primarily consists of a press release (Exhibit 99.1) detailing these financial outcomes. While the filing itself does not contain the specific financial figures or operational details, it serves as a formal notification to investors that this information has been disseminated. Investors seeking detailed insights into Lilly's performance for the first quarter of 2026 should refer to the attached press release, which is incorporated by reference into this filing.
ELI LILLY & Co 8-K Report, Financial Results (Feb 4, 2026)
Eli Lilly and Company (LLY) filed a 8-K Current Report on February 4, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily incorporates by reference a press release (Exhibit 99.1) containing these detailed financial outcomes. While the filing itself is brief, the associated press release is the critical document for investors seeking to understand the company's recent performance, including key revenue drivers, profitability, and any forward-looking statements or guidance provided by management.
ELI LILLY & Co 8-K Report, Executive Changes (Nov 21, 2025)
Eli Lilly & Company (LLY) announced a significant addition to its Board of Directors, electing Dr. Carolyn R. Bertozzi, a distinguished professor from Stanford University and Howard Hughes Medical Institute investigator, effective December 8, 2025. Dr. Bertozzi brings a wealth of expertise in Chemistry, Chemical & Systems Biology, and Radiology, positions that will be highly relevant to Lilly's ongoing innovation and development in the pharmaceutical sector. Her appointment is intended to bolster the Board's strategic direction, particularly through her service on the Science and Technology Committee and the Ethics and Compliance Committee. Dr. Bertozzi's independence has been confirmed, and she will participate in the company's standard director compensation. This move signals Lilly's commitment to leveraging cutting-edge scientific knowledge at the highest governance level.
ELI LILLY & Co 8-K Report, Financial Results (Oct 30, 2025)
Eli Lilly & Company (LLY) filed a Form 8-K on October 29, 2025, to announce its financial results for the third quarter ended September 30, 2025. The filing incorporates by reference a press release, dated October 30, 2025, which contains the detailed financial performance for the period. While the 8-K itself is brief, the attached press release (Exhibit 99.1) is expected to provide investors with crucial insights into the company's revenue, earnings per share, product sales performance, and potentially guidance for the remainder of the fiscal year.
ELI LILLY & Co 8-K Report, Corporate Update (Aug 20, 2025)
Eli Lilly and Company (LLY) has announced the successful completion of a significant debt offering, raising approximately $6.71 billion in net proceeds after underwriting discounts and before expenses. This capital raise involves the issuance of multiple tranches of notes, including $750 million in Floating Rate Notes due 2028 and various fixed-rate notes with maturities ranging from 2028 to 2065. The fixed-rate notes carry coupon rates from 4.000% to 5.650% per annum, while the floating-rate notes are tied to Compounded SOFR plus a spread. This substantial debt issuance is likely intended to support Eli Lilly's ongoing research and development efforts, potential acquisitions, or to strengthen its balance sheet. The diversity in note maturities and the inclusion of floating-rate notes suggest a strategic approach to managing interest rate risk and financing its long-term growth initiatives. Investors should monitor how these proceeds are deployed and their impact on the company's financial leverage and future profitability.
ELI LILLY & Co 8-K Report, Financial Results (Aug 7, 2025)
Eli Lilly & Company (LLY) has filed an 8-K report on August 7, 2025, to announce its financial results for the quarter ended June 30, 2025. The report primarily references a press release, filed as Exhibit 99.1, which contains the detailed financial outcomes for the period. Investors should refer to this press release for specifics regarding revenue, earnings, and other key financial metrics. While the 8-K itself does not provide the detailed financial figures, it serves as the official notification mechanism for the release of this information. The filing indicates that the company's financial performance for the second quarter of 2025 has been disclosed. Investors are advised to review the accompanying press release for a comprehensive understanding of Lilly's operational and financial condition as of June 30, 2025, which will inform their investment decisions.
ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 8, 2025)
Eli Lilly and Company (LLY) held its 2025 Annual Meeting of Shareholders on May 5, 2025, with a strong turnout of approximately 89% of outstanding shares represented. The meeting's primary focus was on voting matters, including the election of directors, advisory approval of executive compensation, and ratification of the independent auditor. All management-proposed items, such as the election of the four director nominees and the ratification of Ernst & Young LLP as the independent auditor, received overwhelming support from shareholders, indicating strong confidence in the company's leadership and governance. However, two significant shareholder proposals to amend the company's Articles of Incorporation – one to eliminate the classified board structure and another to eliminate supermajority voting provisions – failed to receive the required 80% of outstanding shares for approval. While a majority of votes cast were in favor of these changes, the high threshold for approval was not met. This outcome suggests that while a portion of shareholders desire more immediate board changes and simplified voting, the current board structure and voting requirements remain in place, supported by a significant majority.
ELI LILLY & Co 8-K Report, Financial Results (May 1, 2025)
Eli Lilly & Company (LLY) has filed a Form 8-K on April 30, 2025, to report on its financial results for the quarter ended March 31, 2025. The filing primarily directs investors to an attached press release (Exhibit 99.1) for detailed information regarding the company's operational and financial performance during the first quarter of 2025. This standard procedure allows the company to disseminate its earnings information to the public promptly. Investors should review Exhibit 99.1, which contains the full financial results and management's commentary. While this 8-K filing itself does not contain the detailed financial figures, it serves as the official notification and public availability mechanism for the company's quarterly earnings announcement. Key metrics, revenue drivers, and forward-looking statements are expected to be elaborated within the press release.
ELI LILLY & Co 8-K Report, Corporate Update (Feb 12, 2025)
Eli Lilly and Company (LLY) has filed an 8-K detailing a significant debt offering, successfully raising approximately $6.46 billion in net proceeds through the issuance of various senior notes. The offering includes $1 billion in 4.550% Notes due 2028, $1.25 billion in 4.750% Notes due 2030, $1 billion in 4.900% Notes due 2032, $1.25 billion in 5.100% Notes due 2035, $1.25 billion in 5.500% Notes due 2055, and $750 million in 5.600% Notes due 2065. This substantial capital raise will likely be utilized to support the company's ongoing research and development, clinical trials, and potential future acquisitions, aligning with its strategy to expand its product pipeline and market presence. Investors should note the diverse maturity profile and interest rates of these notes, reflecting current market conditions and Lilly's borrowing costs. The company has secured capital across short, medium, and long-term horizons, which can provide financial flexibility. The offering was registered on a Form S-3 registration statement, indicating a routine debt issuance for a company of Lilly's size and financial standing. The specifics of the underwriting agreements and note indentures are detailed in the filed exhibits for those seeking deeper financial insight.
ELI LILLY & Co 8-K Report, Financial Results (Feb 6, 2025)
Eli Lilly and Company (LLY) has filed a Current Report on Form 8-K dated February 6, 2025, to announce its financial results for the quarter and year ended December 31, 2024. While the 8-K itself does not contain the detailed financial figures, it explicitly incorporates by reference Exhibit 99.1, which is a press release detailing these results. Investors should refer to this press release for comprehensive information on the company's performance, including key financial metrics, revenue drivers, and potential forward-looking statements. The filing indicates that the information provided is being furnished and not deemed "filed" for certain regulatory purposes. This is standard practice for earnings releases. The primary takeaway for investors is to access the attached press release (Exhibit 99.1) to understand the company's recent financial health and outlook as presented by management.
ELI LILLY & Co 8-K Report, Financial Results (Jan 14, 2025)
Eli Lilly & Company (LLY) has filed an 8-K report on January 14, 2025, to announce its participation in the 2025 J.P. Morgan Healthcare Conference. During this event, the company is scheduled to provide an update on its 2024 earnings guidance and unveil its revenue guidance range for 2025. This presentation will also include discussions on broader market trends relevant to the pharmaceutical sector. Investors should note that the information being shared is part of a fireside chat and will be accompanied by a press release (Exhibit 99.1) and presentation slides, all of which will be accessible via webcast on Lilly's Investor website. While this 8-K serves to disclose the upcoming events and materials, the provided information is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same regulatory implications as formally filed financial statements. The company will make replays available for approximately 30 days.
ELI LILLY & Co 8-K Report, Executive Changes (Nov 19, 2024)
Eli Lilly and Company (LLY) announced changes to its Board of Directors via an 8-K filing on November 19, 2024. The most significant development for investors is the appointment of Jon Moeller, the current Chairman, President, and CEO of Procter & Gamble, as a new independent director to the LLY Board, effective December 1, 2024. Mr. Moeller brings extensive experience from over two decades in finance, business, and strategy at P&G and will serve on the Audit Committee and the Directors and Corporate Governance Committee. Concurrently, the filing notes the resignation of Karen Walker from the Board, effective December 31, 2024. Ms. Walker, who has served since 2018, is expected to collaborate with the Company on digital commercial activities starting in 2025. Her resignation is confirmed not to be due to any disagreements regarding the Company's operations, policies, or practices. These board changes signal a strategic enrichment of the board's expertise with Mr. Moeller's appointment.
ELI LILLY & Co 8-K Report, Financial Results (Oct 30, 2024)
Eli Lilly & Company (LLY) has filed an 8-K report on October 30, 2024, to announce its financial results for the quarter ended September 30, 2024. The report primarily incorporates by reference a press release (Exhibit 99.1) containing these detailed financial and operational outcomes. While the 8-K itself is procedural, the attached press release will contain the substantive information investors need regarding the company's performance. This includes key metrics such as revenue, earnings per share (EPS), and updates on the company's drug pipeline and sales, particularly for its key growth drivers. Investors should carefully review Exhibit 99.1 for the specific financial figures and strategic commentary provided by the company.
ELI LILLY & Co 8-K Report, Executive Changes (Sep 9, 2024)
Eli Lilly and Company (LLY) has announced a significant leadership change, appointing Lucas Montarce as its new Executive Vice President and Chief Financial Officer, effective September 9, 2024. This appointment follows an extensive search and reflects Mr. Montarce's long tenure and diverse financial leadership experience within Lilly, including his most recent role as president and general manager for the Spain, Portugal, and Greece hub, and prior experience as group vice president, controller, and CFO of Lilly Research Laboratories. Investors should note that this change in CFO is typically a key event, and Mr. Montarce's compensation package includes an annualized base salary of $1,000,000 and an annualized target bonus of $1,000,000. The filing also confirms that Mr. Montarce's appointment was made without any pre-existing arrangements with other individuals, and he has no familial ties to current directors or executive officers, nor is he involved in any related-party transactions requiring disclosure under Regulation S-K. The company has attached a press release detailing this announcement as an exhibit to the 8-K filing. This transition at the CFO level is an important factor for investors to monitor as it can impact financial strategy and reporting going forward.
ELI LILLY & Co 8-K Report, Executive Changes (Aug 16, 2024)
Eli Lilly & Company (LLY) has filed an 8-K report on August 16, 2024, primarily to announce a change in its Board of Directors. Dr. Marschall S. Runge has decided to retire from the Board, with his retirement effective August 31, 2024. The company explicitly states that this decision is not due to any disagreements concerning the Company's operations, policies, or practices. This is a standard procedural filing related to a director's departure.
ELI LILLY & Co 8-K Report, Corporate Update (Aug 14, 2024)
Eli Lilly and Company (LLY) has announced the successful issuance and sale of $4.75 billion in aggregate principal amount of senior notes across multiple tranches, maturing between 2027 and 2064. This significant debt offering, which closed on August 14, 2024, generated net proceeds of approximately $4.96 billion after underwriting discounts. The company utilized this debt issuance to raise substantial capital, likely to support ongoing research and development, potential acquisitions, or general corporate purposes, aligning with its growth strategies in the pharmaceutical sector. Investors should note the diverse maturities and interest rates associated with these notes, ranging from 4.150% for the 2027 Notes to 5.200% for the 2064 Notes. The company has established terms for potential redemption and has outlined conditions under which the principal could become immediately due and payable in the event of a default. This financing action is a key event for the company, demonstrating its ability to access capital markets efficiently.
ELI LILLY & Co 8-K Report, Financial Results (Aug 8, 2024)
Eli Lilly & Company (LLY) filed an 8-K on August 8, 2024, to report its financial results for the quarter ended June 30, 2024. The filing primarily consists of a press release, which is furnished as Exhibit 99.1, detailing the company's operational and financial performance for the period. Investors should refer to this press release for specific figures related to revenue, earnings, and other key financial metrics, as well as management's commentary on the results and outlook. This report does not contain new material information beyond the press release itself. Therefore, the most crucial insights for investors will be found within the provided financial results and any forward-looking statements or guidance shared by Eli Lilly in the accompanying press release. It's important to note that the information furnished under Item 2.02 is not considered "filed" for certain regulatory purposes, but it serves as the primary disclosure vehicle for these quarterly results.
ELI LILLY & Co 8-K Report, Executive Changes (Jul 10, 2024)
Eli Lilly and Company (LLY) has announced a change in its Chief Financial Officer (CFO) role. Anat Ashkenazi will be stepping down from her position as executive vice president and CFO to pursue opportunities outside the pharmaceutical industry. She will remain with the company until the end of July 2024 to ensure a smooth handover of her duties. Taking over as interim CFO, effective July 15, 2024, will be Gordon Brooks. Mr. Brooks brings extensive experience to the role, having been with Eli Lilly for 29 years and holding various senior finance positions. This includes his recent role as group vice president, controller, and corporate strategy, as well as prior leadership positions in financial planning, procurement, and internal audit. The company has stated there are no specific arrangements or understandings related to his selection, no family ties to current executives, and no related-party transactions.
ELI LILLY & Co 8-K Report, Executive Changes (Jun 5, 2024)
Eli Lilly & Co. (LLY) announced a significant leadership change via an 8-K filing on June 5, 2024. Anat Ashkenazi, the Executive Vice President and Chief Financial Officer (CFO), has resigned to pursue opportunities outside the pharmaceutical sector. Ms. Ashkenazi will continue in her role and as a member of the Executive Committee until July 2024, ensuring a smooth transition during this period. The company has initiated a comprehensive search for her successor, considering both internal and external candidates. This CFO transition comes at a critical time for Eli Lilly, a company experiencing substantial growth and development, particularly with its promising drug pipeline. While the departure of a key executive like the CFO can raise questions, Ms. Ashkenazi's commitment to serving through July provides a buffer for leadership continuity. Investors will be closely watching the selection process for her replacement and its potential impact on financial strategy and execution. The press release detailing this announcement is attached as an exhibit to the filing.
ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 9, 2024)
Eli Lilly and Company (LLY) held its 2024 Annual Meeting of Shareholders on May 6, 2024, where a significant majority of outstanding shares (approximately 90%) were represented. The meeting's primary outcome was the election of four director nominees to three-year terms, with overwhelming support from shareholders. Additionally, shareholders advisory approved the compensation of the Company's named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for 2024. However, two key governance proposals seeking to eliminate the classified board structure and supermajority voting provisions did not receive the required 80% of outstanding shares to pass. Several shareholder proposals regarding lobbying activities, diversity and inclusion effectiveness, the impact of patent exclusivities on product access, and the adoption of a comprehensive human rights policy also failed to gain majority approval. These voting outcomes indicate shareholder confidence in the current board and executive compensation, while also signaling a preference to maintain existing governance structures and a lack of consensus on specific governance and social responsibility initiatives presented.
ELI LILLY & Co 8-K Report, Financial Results (Apr 30, 2024)
Eli Lilly and Company (LLY) filed an 8-K on April 30, 2024, primarily to furnish their first-quarter 2024 financial results via an attached press release. While this 8-K does not contain novel operational updates or strategic shifts, it directs investors to the detailed financial performance for the period ending March 31, 2024. Investors should refer to the accompanying press release (Exhibit 99.1) for comprehensive information on revenue, earnings, and other key financial metrics. The significance of this filing lies in its role as the official disclosure mechanism for Lilly's quarterly performance. The press release will contain the specific financial figures, management commentary on the results, and potentially preliminary outlook for the upcoming quarters. Investors are advised to review this press release to understand the company's current financial health and its trajectory.
ELI LILLY & Co 8-K Report, Corporate Update (Feb 9, 2024)
Eli Lilly and Company (LLY) announced on February 7, 2024, its successful issuance of $6.45 billion in aggregate principal amount of senior notes through an underwriting agreement with several major financial institutions. This offering comprised five tranches of notes with varying maturities ranging from 2027 to 2064 and coupon rates from 4.500% to 5.100%. The net proceeds from this significant debt issuance, totaling approximately $6.45 billion after deducting underwriting discounts, are expected to bolster Lilly's financial flexibility. This substantial capital raise indicates Lilly's strategic approach to financing its operations, research and development, and potential future growth initiatives. The diverse maturity profile of the notes allows for a structured approach to debt management. Investors should note that the company retains the option to redeem these notes under specific conditions, and the principal amount may become immediately due and payable in the event of a default, as outlined in the indenture agreement.
ELI LILLY & Co 8-K Report, Financial Results (Feb 6, 2024)
Eli Lilly and Company (LLY) filed an 8-K on February 6, 2024, to report its financial results for the quarter and year ended December 31, 2023. The filing incorporates by reference a press release, dated February 6, 2024, containing these results. While the 8-K itself does not detail the financial figures, it serves as the official notification mechanism for the release of this information to the public and investors. Investors should refer to the accompanying press release (Exhibit 99.1) for specific financial performance data, including revenue, earnings, and guidance for the upcoming periods.
ELI LILLY & Co 8-K Report, Financial Results (Nov 2, 2023)
Eli Lilly and Company (LLY) filed an 8-K on November 2, 2023, primarily to furnish a press release detailing their financial results for the third quarter ended September 30, 2023. While the 8-K itself does not contain the detailed financial data, it directs investors to the accompanying Exhibit 99.1, which is the press release. This filing signifies the official reporting of the company's quarterly performance, providing investors with key metrics on revenue, earnings, and potentially updates on their product pipeline and strategic initiatives. Investors should carefully review the press release (Exhibit 99.1) for comprehensive details on the company's financial health and operational performance during the third quarter. This includes examining the growth drivers, any significant expenses, and the outlook provided by management. The filing is crucial for understanding Lilly's current financial standing and its trajectory moving forward, especially concerning its highly anticipated drug developments.
ELI LILLY & Co 8-K Report, Financial Results (Aug 8, 2023)
Eli Lilly & Company (LLY) filed an 8-K on August 8, 2023, primarily to furnish its second-quarter 2023 financial results. The press release, attached as Exhibit 99.1, details the company's performance for the quarter ended June 30, 2023. While the filing itself is procedural, the attached press release contains the substantive financial and operational data that investors will scrutinize. Investors should focus on the details within the press release for insights into revenue growth, profitability, key product performance (especially in areas like diabetes and obesity), and any forward-looking guidance provided by the company. This 8-K serves as the official notification of the release of this crucial financial information, marking a point for market analysis of Lilly's recent performance and future outlook.
ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 4, 2023)
Eli Lilly and Company (LLY) filed an 8-K report detailing the results of its 2023 Annual Meeting of Shareholders held on May 1, 2023. The report indicates strong shareholder participation, with approximately 90% of outstanding shares represented. Key outcomes include the election of four director nominees to three-year terms and the advisory approval of executive compensation. Shareholders also voted to continue advisory votes on executive compensation on an annual basis and ratified the appointment of Ernst & Young LLP as the independent auditor. Notably, proposals to eliminate the company's classified board structure and to remove supermajority voting provisions did not achieve the required 80% shareholder approval. Several shareholder proposals concerning lobbying activities, patent exclusivity impacts, abortion support risks, diversity and inclusion efforts, and political expenditure reporting were also not approved.
ELI LILLY & Co 8-K Report, Financial Results (Apr 27, 2023)
Eli Lilly and Company (LLY) filed an 8-K on April 27, 2023, primarily to report its financial results for the quarter ended March 31, 2023. The report references an attached press release (Exhibit 99.1) containing the detailed financial outcomes for the period. While the 8-K itself does not contain the specific financial figures, it signals the public disclosure of the company's performance, which investors should review in the accompanying press release for insights into revenue, earnings, and other key financial metrics. This filing is routine for publicly traded companies and serves as a formal notification of material events. For investors, the crucial information lies within the unaudited interim financial results for the first quarter of 2023, which will provide an update on the company's operational and financial condition. Key areas to scrutinize in the press release will include product sales performance, earnings per share (EPS), any forward-looking guidance, and significant developments or challenges encountered during the quarter.
ELI LILLY & Co 8-K Report, Executive Changes (Mar 17, 2023)
Eli Lilly & Company (LLY) filed an 8-K on March 17, 2023, to disclose a non-competition and non-solicitation agreement entered into with Daniel Skovronsky, a key officer. This agreement outlines restrictions on competitive activities and solicitation of company relationships for a period following his employment. The agreement includes a provision for Dr. Skovronsky to receive up to $5 million if the Company chooses to enforce its terms. This filing is primarily an administrative disclosure regarding executive compensation and post-employment obligations, rather than a report of significant operational changes or financial performance. Investors should note this as part of the company's standard governance practices for executive arrangements.
ELI LILLY & Co 8-K Report, Corporate Update (Feb 24, 2023)
Eli Lilly and Company (LLY) announced on February 23, 2023, the successful issuance and sale of a substantial debt offering totaling approximately $4 billion. This offering consisted of four tranches of notes with varying maturities and coupon rates: $750 million of 5.000% Notes due 2026, $1 billion of 4.700% Notes due 2033, $1.25 billion of 4.875% Notes due 2053, and $1 billion of 4.950% Notes due 2063. The net proceeds from this offering, estimated at approximately $3.96 billion after underwriting discounts and before other expenses, are expected to provide significant financial flexibility for the company. This substantial capital raise indicates Lilly's strategic intent to strengthen its balance sheet, potentially to fund ongoing research and development, business development activities, or general corporate purposes. Investors should note the long-term nature of some of these notes, particularly the 2053 and 2063 tranches, reflecting the company's long-term financial planning and commitment to growth. The details of the underwriting agreement and the terms of the notes have been filed with the SEC, offering transparency on the transaction.
ELI LILLY & Co 8-K Report, Financial Results (Feb 2, 2023)
Eli Lilly and Company (LLY) filed an 8-K on February 2, 2023, primarily to furnish its earnings press release for the quarter and year ended December 31, 2022. While the 8-K itself is brief and mainly procedural, it directs investors to the attached Exhibit 99.1, which contains the detailed financial results and operational highlights. This press release is the key document for understanding Lilly's performance during the specified period. Investors should review the press release (Exhibit 99.1) for crucial information regarding revenue, earnings per share, product sales, and any forward-looking guidance provided by the company. This filing serves as the official channel for disseminating these important financial updates, enabling investors to assess the company's current financial health and future prospects.
ELI LILLY & Co 8-K Report, Financial Results (Dec 13, 2022)
Eli Lilly & Company (LLY) filed an 8-K on December 13, 2022, to announce its financial guidance for the fiscal year 2023. This filing is primarily focused on providing forward-looking financial expectations to investors, which were also discussed during a teleconference for analysts and media held on the same day. The press release containing this guidance is attached as Exhibit 99.1 to the 8-K. While the 8-K itself does not contain detailed financial results or operational updates, it serves as the official channel for disseminating the company's strategic financial outlook for the upcoming year. Investors should refer to the attached Exhibit 99.1 for the specific figures and assumptions underpinning Lilly's 2023 financial projections, which will be crucial for evaluating the company's anticipated performance and growth trajectory.
ELI LILLY & Co 8-K Report, Financial Results (Nov 1, 2022)
Eli Lilly & Company's 8-K filing on November 1, 2022, primarily serves to furnish their financial results for the quarter ended September 30, 2022. The press release, attached as Exhibit 99.1, contains the detailed operational and financial condition information. Investors should refer to this exhibit for specific metrics regarding the company's performance during the third quarter of 2022. While the 8-K itself is a notification of the release of financial information, it directs investors to the accompanying press release for the substantive details. This typically includes revenue figures, earnings per share, segment performance, and forward-looking guidance, all crucial for assessing the company's current financial health and future prospects.
ELI LILLY & Co 8-K Report, Corporate Update (Oct 12, 2022)
Eli Lilly and Company (LLY) has filed an 8-K report for the event date of October 11, 2022, to disclose estimated charges for acquired In-Process Research and Development (IPR&D) and development milestones for the third quarter of 2022. The company anticipates these charges to be approximately $62.4 million on a pre-tax basis, which is expected to result in a charge of $0.06 per share for both GAAP and non-GAAP earnings. These figures are preliminary and subject to finalization of financial closing procedures, with no assurance that actual results will not differ.
ELI LILLY & Co 8-K Report, Financial Results (Aug 4, 2022)
Eli Lilly and Company (LLY) filed an 8-K on August 4, 2022, primarily to announce its financial results for the quarter ended June 30, 2022. The key information regarding these results is contained within the press release attached as Exhibit 99.1. Investors should refer to this press release for details on revenue, earnings, and any other operational or financial performance metrics for the second quarter of 2022. This filing serves as the official notification of these results, indicating that the company has met its reporting obligations. While the 8-K itself is brief and procedural, the attached press release is the critical document for understanding Lilly's performance during the reported period and its implications for the company's financial condition and future outlook.
ELI LILLY & Co 8-K Report, Executive Changes (May 6, 2022)
This Eli Lilly & Co. (LLY) 8-K filing announces a significant addition to its Board of Directors with the appointment of Dr. Mary Lynne Hedley, effective May 15, 2022. Dr. Hedley brings a wealth of experience in the biotechnology and oncology sectors, having co-founded TESARO, Inc., a successful oncology therapeutics company acquired by GlaxoSmithKline. Her expertise in scientific research, development, and commercialization is expected to be a valuable asset to Lilly's strategic direction. Dr. Hedley's appointment to the Board's Ethics and Compliance Committee and Science and Technology Committee underscores Lilly's commitment to robust governance and innovation. Her independence is confirmed, and she will participate in the company's standard director compensation program. This move signals Lilly's continued focus on strengthening its leadership with seasoned industry professionals.
ELI LILLY & Co 8-K Report, Rights Modification (May 4, 2022)
Eli Lilly and Company (LLY) filed an 8-K on May 4, 2022, detailing material modifications to its corporate governance documents following its Annual Shareholder Meeting held on May 2, 2022. The most significant update is the amendment to the Articles of Incorporation and Bylaws, which now allows shareholders to amend the Bylaws with a majority vote, in addition to the Board of Directors. This change shifts some bylaw amendment power from the Board directly to the shareholders. While shareholders approved this change, other significant governance proposals, such as eliminating the classified board structure and removing supermajority voting provisions, did not receive the required 80% shareholder approval. Additionally, several shareholder proposals related to lobbying activities and risk oversight were not approved. The appointment of Ernst & Young LLP as the independent auditor was ratified, and the compensation of named executive officers was approved on an advisory basis. The company also reported strong voting turnout, with approximately 90% of outstanding shares participating in the meeting.
ELI LILLY & Co 8-K Report, Financial Results (Apr 28, 2022)
Eli Lilly and Company (LLY) filed an 8-K on April 28, 2022, to report its financial results for the quarter ended March 31, 2022. The report primarily incorporates by reference a press release, dated April 28, 2022, which contains the detailed financial outcomes and operational updates for the period. Investors should refer to the attached Exhibit 99.1 for the specific figures, including revenue, earnings, and any forward-looking guidance. While this 8-K filing itself is brief and serves to officially attach the earnings press release, the substance of the company's performance and outlook for the first quarter of 2022 is contained within that press release. Investors seeking to understand Lilly's financial condition and results of operations for the specified quarter need to examine the detailed information provided in Exhibit 99.1. This includes key financial metrics and any business developments announced by the company.
ELI LILLY & Co 8-K Report, Financial Results (Apr 14, 2022)
Eli Lilly & Company (LLY) has filed an 8-K to announce a change in how it will present its non-GAAP financial measures, effective with its first quarter 2022 earnings release. The company will no longer include adjustments for upfront charges and development milestones related to acquired in-process research and development (IPR&D) projects in its non-GAAP presentations. This change is in response to updated guidance from the SEC. While the company has not finalized its Q1 2022 results, it anticipates approximately $165 million in IPR&D charges for the quarter, which would have an estimated impact of $0.15 per share under the previous non-GAAP reporting method. Investors should note that this information is being furnished and not deemed filed, meaning it does not carry the same regulatory implications as a filed document. The company will provide updated historical financial information reflecting this new presentation on its investor website.
ELI LILLY & Co 8-K Report, Financial Results (Feb 3, 2022)
Eli Lilly and Company (LLY) filed an 8-K on February 3, 2022, to report its financial results for the fourth quarter and full year ended December 31, 2021. The primary purpose of this filing is to provide investors with access to the company's official earnings press release, which contains detailed financial performance data. Investors should refer to the attached Exhibit 99.1 for the comprehensive financial outcomes, including revenue, earnings, and any forward-looking guidance provided by the company. This 8-K filing is a standard procedure to disseminate material financial information. While the 8-K itself is brief, it serves as the official notification and gateway to the detailed financial results presented in the accompanying press release. Investors looking to understand Lilly's performance in the period ending December 31, 2021, and its outlook should carefully review the press release.
ELI LILLY & Co 8-K Report, Corporate Update (Jan 31, 2022)
Eli Lilly and Company (LLY) announced on January 31, 2022, its intention to redeem all outstanding €600,000,000 of its 1.000% Notes due 2022. The redemption is scheduled to occur on March 2, 2022. This action represents a proactive financial management strategy by Lilly, likely aimed at optimizing its capital structure or reducing interest expenses.
ELI LILLY & Co 8-K Report, Bylaw Amendment (Dec 16, 2021)
Eli Lilly and Company (LLY) filed an 8-K on December 15, 2021, to announce an amendment and restatement of its bylaws, effective December 13, 2021. The changes primarily focus on procedural and disclosure requirements for director nominations and shareholder proposals, flexibility in scheduling the annual shareholder meeting, and modernization of meeting procedures. These amendments are largely administrative and intended to streamline corporate governance, rather than signaling significant shifts in the company's strategic or financial direction. Investors should note that these bylaw amendments do not directly impact the company's financial performance or product pipeline. However, the increased flexibility in scheduling the annual meeting and refined procedures for shareholder engagement are important governance aspects. The adoption of gender-neutral terms and other clarifying changes reflect a commitment to modernizing corporate practices.
ELI LILLY & Co 8-K Report, Financial Results (Dec 15, 2021)
Eli Lilly & Co. (LLY) filed an 8-K on December 15, 2021, primarily to announce updates to its financial guidance for both 2021 and 2022. This filing signals a proactive communication strategy from the company regarding its financial outlook. While the 8-K itself does not contain detailed financial results, it directs investors to a press release (Exhibit 99.1) issued on the same date, which elaborates on these guidance updates. This press release was further discussed during a teleconference for analysts and media, indicating the company's commitment to transparency and providing context for its financial projections to the investment community. Investors should pay close attention to the specifics of the updated guidance outlined in the press release. This includes any changes to revenue forecasts, earnings per share (EPS) expectations, and any factors influencing these projections, such as product performance, pipeline developments, or market conditions. The 2022 guidance is particularly important as it offers a forward-looking view of the company's expected performance in the upcoming fiscal year, allowing investors to assess its growth trajectory and potential returns.
ELI LILLY & Co 8-K Report, Financial Results (Oct 26, 2021)
Eli Lilly & Company (LLY) filed an 8-K on October 26, 2021, to report its financial results for the third quarter ended September 30, 2021. The report primarily directs investors to an attached press release (Exhibit 99.1) for detailed financial performance and operational updates. This filing serves as the official notification of these results to the market, without triggering the same level of regulatory scrutiny as if the information were 'filed' under Section 18 of the Exchange Act.
ELI LILLY & Co 8-K Report, Corporate Update (Sep 10, 2021)
Eli Lilly and Company (LLY) announced on September 9, 2021, that it entered into an underwriting agreement to issue and sell a significant amount of senior notes. The offering includes €600 million of 0.500% Notes due 2033, €500 million of 1.125% Notes due 2051, €700 million of 1.375% Notes due 2061, and £250 million of 1.625% Notes due 2043. This debt issuance aims to raise capital for the company, with an expected closing date of September 14, 2021. The proceeds from these offerings, after underwriting discounts, are substantial, totaling approximately €596.3 million for the 2033 Notes, €485.7 million for the 2051 Notes, €680.0 million for the 2061 Notes, and £243.3 million for the 2043 Notes. These funds will likely support Lilly's ongoing research and development initiatives, pipeline expansion, or general corporate purposes, reflecting the company's strategic financial management to fuel future growth.
ELI LILLY & Co 8-K Report, Executive Changes (Aug 25, 2021)
Eli Lilly and Company (LLY) announced a significant development through a multi-year research collaboration and licensing agreement with Lycia Therapeutics, Inc. This strategic partnership aims to advance innovative therapeutic approaches. As a consequence of this new agreement, a key member of the Board of Directors, Carolyn R. Bertozzi, has resigned. Dr. Bertozzi, who is also the academic founder of Lycia Therapeutics, stepped down from the Board effective August 23, 2021. The company has clarified that her resignation is not due to any disputes or disagreements regarding the company's operations or policies. This move signifies a potential shift in focus for Dr. Bertozzi and may indicate Lilly's commitment to exploring novel research avenues through this collaboration.
ELI LILLY & Co 8-K Report, Executive Changes (Aug 17, 2021)
Eli Lilly and Company (LLY) announced on August 17, 2021, that Alfonso Zulueta, Senior Vice President and President of Lilly International, will retire effective December 26, 2021. This leadership transition is a significant event for the company, as Mr. Zulueta has held a key role in the company's international operations. Investors should monitor the company's strategic succession planning and how this change might impact Lilly's global market performance and future growth initiatives. The announcement was made via a press release filed as part of an 8-K filing. While the filing primarily details Mr. Zulueta's upcoming retirement, it also references other corporate changes mentioned in the press release. Investors are encouraged to review the full press release (Exhibit 99.1) for comprehensive details on any additional organizational adjustments that may affect the company's operational structure and future outlook.
ELI LILLY & Co 8-K Report, Financial Results (Aug 3, 2021)
Eli Lilly and Company (LLY) filed an 8-K on August 3, 2021, to report its financial results for the quarter ended June 30, 2021. The filing primarily consists of a press release (Exhibit 99.1) which contains the company's unaudited financial results for the period. Investors should review this press release for details on the company's operational and financial performance during the second quarter of 2021. This report serves as a notification of the release of these results, with the detailed financial information contained within the attached exhibit.
ELI LILLY & Co 8-K Report, Corporate Update (May 27, 2021)
Eli Lilly and Company (LLY) disclosed on May 26, 2021, that it received a subpoena from the U.S. Department of Justice (DOJ) concerning its manufacturing site in Branchburg, New Jersey. This subpoena is part of an ongoing investigation into allegations related to the Branchburg facility. Lilly stated that it is cooperating fully with the DOJ and has also initiated its own independent investigation through external counsel to thoroughly examine the allegations. The company emphasized its strong commitment to manufacturing high-quality medicines and prioritizing patient safety and product quality. While the exact nature of the allegations and the scope of the DOJ's investigation are not detailed in this filing, investors should note that such governmental inquiries can potentially lead to significant legal, regulatory, and financial repercussions. Lilly's proactive stance in cooperating with the DOJ and conducting its own internal review suggests an effort to address the situation transparently. However, the potential impact on Lilly's operations, reputation, and financial performance remains uncertain at this stage, pending the outcome of these investigations.